Literature DB >> 2850132

Acute and long-term renal effects of angiotensin converting enzyme inhibition in normotensive, normoalbuminuric insulin-dependent diabetic patients.

M M Pedersen1, A Schmitz, E B Pedersen, H Danielsen, J S Christiansen.   

Abstract

Glomerular filtration rate (GFR) (thalamate clearance), renal plasma flow (RPF) (hippuran clearance), and urinary albumin excretion rate (AER) were measured in 10 normoalbuminuric, normotensive insulin-dependent diabetic patients and 8 normal subjects before and during acute angiotensin converting enzyme (ACE) inhibition by means of enalapril (10 mg IV). The effect of placebo versus enalapril (30 mg day-1) was also studied for 3-month treatment periods in the insulin-dependent diabetic patients. Acute ACE-inhibition caused a decline in filtration fraction (FF) from 0.259 +/- 0.011 (+/- SE) to 0.237 +/- 0.013 (2p less than 0.01) in the diabetic patients, and from 0.210 +/- 0.010 to 0.188 +/- 0.006 (2p less than 0.02) in the normal subjects. Mean arterial blood pressure was lowered from 90 +/- 1 to 84 +/- 2 mmHg (2p less than 0.01) and from 91 +/- 1 to 86 +/- 2 mmHg (2p less than 0.05). No significant change in blood glucose, AER or fractional albumin excretion (theta Alb) was seen in either group. After 3 months of enalapril treatment FF was decreased from 0.253 +/- 0.011 to 0.235 +/- 0.011 (2p less than 0.05), AER from 5.6 x/ divided by 1.7 to 4.3 x/divided by 1.6 micrograms min-1 (2p less than 0.01) and theta Alb from 1.22 +/- 0.22 x 10(-6) to 0.92 +/- 0.12 x 10(-6) (2p less than 0.02). The decline in total renal resistance was not significant (0.175 +/- 0.013 to 0.165 +/- 0.012 mmHg ml-1 min-1) and significant changes in GFR, RPF, mean arterial pressure or HbA1c were not observed.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2850132     DOI: 10.1111/j.1464-5491.1988.tb01052.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  9 in total

1.  Diabetic nephropathy: evidence for renoprotection and practice.

Authors:  C E Mogensen
Journal:  Heart       Date:  2000-09       Impact factor: 5.994

2.  Angiotensin converting enzyme inhibitors and diabetic nephropathy.

Authors:  C E Mogensen
Journal:  BMJ       Date:  1992-02-08

Review 3.  Recent Advances in Pharmacological Management of Hypertension in Diabetic Patients with Nephropathy : Effects of Antihypertensive Drugs on Kidney Function and Insulin Sensitivity.

Authors:  Tsuneharu Baba; Takashi Ishizaki
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

4.  Acute renal effects of angiotensin converting enzyme inhibition in microalbuminuric type 1 diabetic patients.

Authors:  K W Hansen; M M Pedersen; J S Christiansen; C E Mogensen
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

Review 5.  Renoprotective role of ACE inhibitors in diabetic nephropathy.

Authors:  C E Mogensen
Journal:  Br Heart J       Date:  1994-09

6.  Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy.

Authors:  H H Parving; E Hommel; M Damkjaer Nielsen; J Giese
Journal:  BMJ       Date:  1989-08-26

7.  Enalapril reduces microalbuminuria in young normotensive type 1 (insulin-dependent) diabetic patients irrespective of its hypotensive effect.

Authors:  S Rudberg; A Aperia; U Freyschuss; B Persson
Journal:  Diabetologia       Date:  1990-08       Impact factor: 10.122

8.  Comparison of reduction in microalbuminuria by enalapril and hydrochlorothiazide in normotensive patients with insulin dependent diabetes.

Authors:  M Hallab; Y Gallois; G Chatellier; V Rohmer; P Fressinaud; M Marre
Journal:  BMJ       Date:  1993-01-16

9.  Long-term treatment with nifedipine reduces urinary albumin excretion and glomerular filtration rate in normotensive type 1 diabetic patients with microalbuminuria.

Authors:  C Schnack; M Capek; M Banyai; A Kautzky-Willer; R Prager; G Schernthaner
Journal:  Acta Diabetol       Date:  1994-04       Impact factor: 4.280

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.